ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections Nasdaq:ADMA

ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections Nasdaq:ADMA

News Highlights

RAMSEY, N.J. and BOCA RATON, Fla. and KENNESAW, Ga., March 03, 2021 (News) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its plasma collection center located in Kennesaw, Georgia received approval from the Korean Ministry of Food and Drug Safety (MFDS) for the sale of source plasma into South Korea. In conjunction with the South Korean approval, ADMA additionally announced the Kennesaw plasma collection center received FDA approval to implement a Hepatitis B immunization program, enabling ADMA to collect source plasma from donors immunized with an FDA-licensed Hepatitis B vaccine.

“These approvals demonstrate ADMA’s strict adherence to the regulatory requirements of the global plasma community and build upon the significant regulatory milestones already achieved by our Company in 2021,” said Adam Grossman, President and Chief Executive Officer of ADMA Biologics. “The approvals announced today further enhance our existing global presence as a source plasma provider, which includes the United States and now South Korea. Our BioCenters expansion strategy remains comfortably on track, and these approvals represent another important step towards our objective of further securing our raw material supply chain and enhancing our end-to-end control of manufacturing operations.”

About ADMA BioCenters

ADMA BioCenters is an FDA licensed facility specializing in the collection of human plasma used to make special medications for the treatment and prevention of diseases. Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional and pleasant donation environment. ADMA BioCenters strictly follows FDA regulations and guidance and enforces cGMP (current good manufacturing practices) in all of its facilities. For more information about ADMA BioCenters, please visit www.admabiocenters.com.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “intend,” “target,” “plan,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s objective of further securing its raw material supply chain and enhancing its end-to-end control of manufacturing operations. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

COMPANY CONTACT: Skyler BloomDirector, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:Sam MartinManaging Director, Argot Partners | 212-600-1902 | sam@argotpartners.com

 

  • Check the latest Health news updates and information.
  • Please share this news ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections Nasdaq:ADMA with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Jim Cramer withdrew half of his ‘fake money’ Bitcoin to pay the mortgage

Jim Cramer withdrew half of his ‘fake money’ Bitcoin to pay the mortgage

Twitter user “SZ BeatzCoin” likened Cramer selling to the infamous pizza purchase for 10,000 BTC. “It was like, kind of, phoney money paying for real money,” ...
Irsay family intensifies efforts to raise awareness about mental health |  sports

Irsay family intensifies efforts to raise awareness about mental health | sports

“We both – even from the start of the PSAs to now – continually get letters and stories, and we read every single one of them,” Colts vice chair/owner Kalen ...
City Council OKs pedicab business, docking stations for scooters |  Local News

City Council OKs pedicab business, docking stations for scooters | Local News

kAmp7E6C 2 3C:67 5:D4FDD:@?k^Am kAmw6865FD D2:5 96’D ?6G6C @A6C2E65 2 A65:423 367@C6k^Am kAmp=D@ 2AAC@G65 3J E96 r:EJ r@F?4:= @? |@?52J H2D E96 =@42E:@? @7 ?6H ...
Morgan Stanley confirms that Wealth Management customers have access to 2 cryptographic funds

Morgan Stanley confirms that Wealth Management customers have access to 2 cryptographic funds

Source finance.yahoo.com (Bloomberg) — The physical crude market in Asia has been reinvigorated amid a rise in buying by a Chinese mega-refiner as well ...
Brave Souls is a new RPG Gacha for PS4 in 2021

Brave Souls is a new RPG Gacha for PS4 in 2021

We don’t have a specific date on when Bleach: Brave Souls will arrive on the PS4, but we do know that the game will be celebrating its sixth anniversary on ...
Explanation of Nintendo’s “No Politics” advertising campaign

Explanation of Nintendo’s “No Politics” advertising campaign

To modern audiences, seeing Mario pelt an innocent man with a green shell and brazenly celebrate the act is extremely odd. Since this commercial in 2003, ...
For new MetroWest business owners, the pandemic was the final obstacle

For new MetroWest business owners, the pandemic was the final obstacle

The distillery, which now offers appetizers, entrees and desserts to go along with grain-to-glass spirits, began operating as a takeout business in May. ...
Look for financial empowerment, long-term solutions beyond COVID-19

Look for financial empowerment, long-term solutions beyond COVID-19

More from LSJ opinion This year, just covering rent and utilities has been a significant challenge for most clients, so financial coach Velma Kyser sought out ...
Local health officials point to Johnson & Johnson’s pause as ‘plenty of caution’ and recommend continued vaccination |  Regional News

Local health officials point to Johnson & Johnson’s pause as ‘plenty of caution’ and recommend continued vaccination | Regional News

Less than 3% of vaccinations distributed by the Aspirus system have included Johnson & Johnson vials, according to the company release. Aspirus Health, ...
Show next
Compsmag - Latest News from tech, business and health
Logo